T3	eligibility 403 515	Patients with human epidermal growth factor receptor 2-normal, chemotherapy-na√Øve metastatic breast cancer (MBC)
T4	total-participants 850 853	123
T5	total-participants 875 878	122
T6	outcome 1001 1025	Grade 3 or 4 neutropenia
T1	intervention 60 71	ixabepilone
T7	control 75 102	paclitaxel plus bevacizumab
T8	iv-bin-percent 1052 1056	60 %
T9	iv-bin-percent 1071 1075	16 %
T10	cv-bin-percent 1083 1087	22 %
T12	iv-bin-percent 1159 1161	48
T13	iv-bin-percent 1163 1165	71
T14	cv-bin-percent 1171 1175	63 %
T15	outcome 1212 1244	Median progression-free survival
T16	iv-cont-median 1271 1281	9.6 months
T17	iv-cont-median 1292 1303	11.9 months
T18	cv-cont-median 1318 1329	13.5 months
T2	outcome 1151 1154	ORR
